<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 14, 1998
--------------------------
Oncormed, Inc.
--------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware
--------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
00-13768 52-1842781
- -------------------------- --------------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
205 Perry Parkway, Gaithersburg, Maryland 20877
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(301) 208-1888
----------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
N.A.
----------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE> 2
Item 5. Other Events
The Company and Oncor, Inc. are parties to the following
technology license agreements: (1) the Technology License
Agreement, dated July 12, 1993, (2) the Restated Technology
Agreement, dated June 6, 1994, and (3) the Amended and
Restated Technology License Agreement, dated February 24,
1997 (collectively, the "Technology Agreement"). On June 6,
1994, the Company issued to Oncor, Inc. a Convertible
Subordinated Promissory Note (the "Note") in the original
principal amount of $715,751. On November 13, 1997, the
Company and Oncor, Inc. entered into a letter agreement
regarding BRCA1 and BRCA2 technology (the "BRCA
Agreement").
On September 14, 1998, the Company and Oncor, Inc. entered
into a Termination Agreement (the "Termination Agreement"),
which, among other things, terminated the Technology
Agreement and the BRCA Agreement. All amounts to be paid by
the Company to Oncor or Oncor to the Company under the
Technology Agreement or the BRCA Agreement are being waived
and forgiven in full. In addition, under the Termination
Agreement, the Note shall be automatically cancelled upon
payments by the Company to Oncor, Inc. in an aggregate
amount equal to $500,000, with $250,000 being paid on the
date of the Termination Agreement and $250,000 paid upon
the consummation of the merger of the Company with and into
Gene Logic Acquisition Corp., a Delaware corporation and
wholly owned subsidiary of Gene Logic Inc. (the "Merger").
In the event, the Merger is not consummated by December 31,
1998, the remaining principal due and owing to Oncor under
the Note shall be $357,875.50, which amount shall be repaid
to Oncor in accordance with the terms of the Note. A copy
of the Termination Agreement is attached hereto as Exhibit
10.1 and is incorporated herein by reference.
Item 7. Financial Statements and Exhibits
(c) Exhibits
Exhibit Number Description
10.1 Termination Agreement, dated September 14, 1998.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Oncormed, Inc.
----------------------------------------------
(Registrant)
By: /s/ DOUGLAS DOLGINOW
-------------------------------------
Name: Douglas Dolginow
-------------------------------------
Title: President and Chief Operating Officer
-------------------------------------
Dated: September 22, 1998
<PAGE> 1
Exhibit 10.1
TERMINATION AGREEMENT
THIS TERMINATION AGREEMENT ("Agreement") is made and entered into as of
September 14, 1998 (the "Effective Date"), by and between ONCORMED, INC.
("Oncormed"), a Delaware corporation and ONCOR, INC. ("Oncor"), a Maryland
corporation (each of Oncormed and Oncor may hereinafter be referred to as a
"Party" and collectively they shall be referenced as the "Parties").
RECITALS
WHEREAS, Oncor and Oncormed have been or are parties to that certain
(A)(i) Technology License Agreement, dated July 12, 1993, (ii) Restated
Technology License Agreement, dated June 6, 1994, (iii) Amended and Restated
Technology License, dated February 24, 1997 (collectively, the "Technology
Agreement"), and (B) that certain letter agreement dated November 13, 1997 as to
BRCA 1 and BRCA 2 technology (the "BRCA Agreement");
WHEREAS, each of Oncormed and Oncor have certain rights and obligations
pursuant to the Technology Agreement and the BRCA Agreement;
WHEREAS, Oncor holds that certain Convertible Subordinated Promissory Note
dated June 6, 1994 (the "Oncormed Note") of Oncormed in the original principal
amount of $715,751;
WHEREAS, the technology owned by Oncormed and licensed to Oncor pursuant
to the Technology Agreement and BRCA Agreement is valuable to Oncormed and
Oncormed wishes to regain all ownership and license rights to such technology,
WHEREAS, the technology owned by Oncor and licensed to Oncormed pursuant
to the Technology Agreement is valuable to Oncor and Oncor wishes to regain all
ownership and license rights to such technology;
WHEREAS, the Parties desire to (a) terminate the Technology Agreement and
the BRCA Agreement and all of their respective rights and obligations
thereunder, and (b) satisfy all outstanding indebtedness under the Oncormed Note
and all of their respective rights thereunder in the manner described in this
Agreement: and
WHEREAS, the Parties wish to compromise, settle and discharge any and all
actual or potential claims and controversies arising out of or related to the
Technology Agreement, the BRCA Agreement and the Oncormed Note, regardless of
whether such actual and potential claims are known or unknown.
1.
<PAGE> 2
AGREEMENT
NOW, THEREFORE, in consideration of the promises and mutual covenants,
waivers and releases contained herein, it is hereby agreed by and between the
Parties hereto as follows:
1. TERMINATION OF TECHNOLOGY AGREEMENT AND BRCA AGREEMENT. Upon the
Effective Date, the Technology Agreement and the BRCA Agreement (and any other
prior agreements between the Parties regarding the subject matter of the
Technology Agreement and the BRCA Agreement) and all of the respective rights
and obligations of Oncormed and Oncor thereunder are terminated and of no
further force or effect. All amounts to be paid by Oncormed to Oncor or by Oncor
to Oncormed under the Technology Agreement or the BRCA Agreement (or any such
other predecessor agreement), whether now owing or to be paid in the future, are
hereby waived and forgiven in full, and Oncormed shall not have any obligation
whatsoever to pay to Oncor, and Oncor shall not have any obligation whatsoever
to pay to Oncormed, any monies or other amounts under the Technology Agreement
or the BRCA Agreement. Notwithstanding the termination of the parties rights as
set forth above, not later than October 15, 1998 (i) Oncormed shall use
reasonable efforts to assign to Oncor all of Oncormed's right, title and
interest to the Improvements and the Oncor Technology Improvements (each as
defined in the Technology Agreement) as contemplated by Section 2(b) of the
Technology Agreement, and (ii) Oncor shall use reasonable efforts to assign to
Oncormed any improvements or know-how made or developed by Oncor to any
technology or intellectual property of Oncormed licensed to Oncor by Oncormed
under the Technology Agreement or the BRCA Agreement.
2. SATISFACTION AND CANCELLATION OF ONCORMED NOTE. As partial
consideration for the termination of the Technology Agreement and the BRCA
Agreement and the receipt of an aggregate of $500,000 from Oncormed in the
manner set forth below, Oncor hereby agrees that, upon the consummation of the
proposed merger of Oncormed with Gene Logic Acquisition Corp., a Delaware
corporation and wholly owned subsidiary of Gene Logic Inc. (the "Merger"), the
Oncormed Note shall automatically be cancelled and all principal and interest
owed thereunder shall be deemed fully paid and satisfied. On the Effective Date,
Oncormed will advance to Oncor an aggregate of $250,000. Subject to, and upon
the consummation of, the Merger, which is anticipated to occur on or about
September 29, 1998, (i) Oncormed shall make an additional payment of $250,000 to
Oncor, and (ii) the Oncormed Note shall automatically be cancelled.
Notwithstanding the foregoing, if such Merger is not consummated by December 31,
1998, the remaining principal due and owing to Oncor under the Oncormed
2.
<PAGE> 3
Note shall be $357,875.50, which amount shall be repaid to Oncor in accordance
with the terms of the Oncormed Note.
3. ONCOR RELEASE. Oncor hereby forever, generally and completely releases,
acquits and discharges Oncormed, and each of its officers, directors, agents
servants, shareholders, employees, partners, successors, any surviving
corporation in the event of a merger to which Oncormed is a party, assigns,
affiliates, attorneys, insurers, customers and clients of and from any and all
actual or potential liabilities, demands, causes of action, costs, expenses,
attorneys' fees, damages, indemnities and obligations of every kind and nature,
at law, in equity or otherwise known, or unknown, suspected and unsuspected,
disclosed and undisclosed, arising out of or in any way related to the
Technology Agreement, the BRCA Agreement and the other matters described in this
Agreement (collectively, "Oncor's Actual or Potential Claims"); provided,
however, that nothing in this paragraph shall waive any right to enforce this
Agreement.
4. ONCORMED RELEASE. Oncormed hereby forever, generally and completely
releases, acquits and discharges Oncor, and each of its officers, directors,
agents servants, shareholders, employees, partners, successors, assigns,
affiliates, attorneys, insurers, customers and clients of and from any and all
actual or potential liabilities, demands, causes of action, costs, expenses,
attorneys' fees, damages, indemnities and obligations of every kind and nature,
at law, in equity or otherwise known, or unknown, suspected and unsuspected,
disclosed and undisclosed, arising out of or in any way related to the
Technology Agreement, the BRCA Agreement and the other matters described in this
Agreement (collectively, "Oncormed's Actual or Potential Claims"), provided,
however, that nothing in this paragraph or this Agreement shall waive any right
to enforce this Agreement. Collectively, Oncormed's Actual or Potential Claims
and Oncor's Actual or Potential Claims shall be referenced as the "Claims."
5. CLAIMS. Each Party specifically denies all actual and potential Claims.
This Agreement is a compromise of existing rights, obligations and claims and
does not reflect in any way either the merits of any of those claims or that
there has been any wrongdoing by any Party. The promises in this Agreement shall
not be construed to be an admission of any liability, fault or obligation
whatsoever by any Party to any other Party to this Agreement or to any other
person whomsoever.
6. KNOWLEDGE OF FACTS. It is understood by the Parties that the facts may
turn out to be other than, or different from, the facts now believed by the
Parties to be true. The only representations and warranties on which the Parties
have relied in entering this Agreement are those set forth in writing within
this Agreement, Each Party expressly assumes the risk of the facts turning out
to be different than they believe them to be, and each Party agrees that the
Agreement shall in all respects be effective and not subject to termination or
rescission because of any such mistaken belief.
3.
<PAGE> 4
7. REPRESENTATIONS AND WARRANTIES. Each Party warrants and in good faith
represents that there has been, and there will be, no assignment or other
transfer to any third party of any interest in any Claims released hereunder,
and the Parties agree to indemnify and hold each other harmless from any
liability, claims, demands, damages, costs, expenses, and attorneys' fees
incurred by any of them as a result of any person asserting any such assignment
or transfer of any rights or Claims released hereunder under any such assignment
or transfer. It is the intention of the Parties that this indemnity does not
require payment as a condition precedent to recovery under this indemnity. The
execution and delivery of this Agreement and the other agreements, documents and
instruments contemplated hereby have been duly and validly authorized by the
Boards of Directors of the Parties and no other corporate proceedings on the
part of the Parties are necessary for Oncor or Oncormed to authorize any of such
agreements, documents or instruments. This Agreement and the other agreements,
documents and instruments to be executed in connection with this Agreement have
been (or will be) duly executed and delivered by duly authorized officers of
Oncor and Oncormed.
8. CONFIDENTIALITY. Each Party agrees that, unless legally required,
otherwise deemed necessary upon advice of counsel or otherwise required under
GAAP to do so it will keep the terms, conditions and amounts of this Agreement
completely confidential and will not disclose any such information to anyone,
except as may be necessary to their officers, directors, necessary employees,
attorneys, accountants, or tax professionals (and only if such persons are made
aware of this confidentiality obligation and are made subject to such obligation
of confidentiality and agree to keep such information confidential).
9. SURVIVAL OF CERTAIN PROVISIONS. Except as expressly provided herein,
each Party agrees that this Agreement shall terminate any provisions of the
Technology Agreement or BRCA Agreement, which, pursuant to the terms of such
agreements, survive the termination of such agreements, except for those
provisions in such agreements specifically relating to confidentiality of
proprietary information of either Party.
10. DRAFTING OF AGREEMENT. The Parties acknowledge that each of the
Parties have participated in the drafting and negotiation of this Agreement. For
purposes of interpreting this document, each provision, paragraph, sentence and
word herein shall be deemed to have been jointly drafted by the Parties. The
Parties intend for this Agreement to be construed and interpreted neutrally in
accordance with the plain meaning of the language contained herein, and not
presumptively construed against any actual or purported drafter of any specific
language contained herein.
11. ACKNOWLEDGEMENT. Each Party acknowledges, agrees and represents that
it: (a) has been represented in negotiations for, and preparation of, this
Agreement by
4.
<PAGE> 5
counsel of that Party's choosing; (b) has read the Agreement and has had it
fully explained by its counsel' (c) is fully aware of the contents and legal
effect of this Agreement; (d) has authority to enter into and sign the
Agreement; and (e) enters into and signs the same of its own free will.
12. BINDING AGREEMENT. This Agreement shall bind the heirs, personal
representatives, successors and assigns of each Party, and inure to the benefit
of each Party, its agents, directors, officers, employees, attorneys, successors
and assigns.
13. ENTIRE AGREEMENT. The Agreement contains the entire agreement between
the Parties hereto and constitutes the complete, final and exclusive embodiment
of their agreement with respect to the subject matter hereof. All prior or
contemporaneous agreements, understandings, representations and statements oral
or written, are merged into and superseded by this Agreement. No claimed
additions to or modifications or amendments of this Agreement, nor any claimed
waiver of any of its terms or conditions, shall be effective unless in writing
and signed by all Parties hereto.
14. INDEMNIFICATION. Each Party will indemnify and hold harmless each
other Party hereto from any loss incurred directly or indirectly by reason of
the falsity or inaccuracy of any representation made in this Agreement.
15. ATTORNEYS' FEES. Should any Party hereto bring an action or proceeding
for the purpose of enforcing this Agreement, then, in such an event the
prevailing party shall be entitled to be reimbursed by the losing party for all
costs and expenses incurred as a result thereof, including, but not limited to,
reasonable attorneys' fees.
16. COSTS. Each Party to this Agreement will bear its own costs, expenses,
and attorneys' fees whether taxable or otherwise incurred in or arising out of
or in any way related to the matters released herein, including without
limitation, costs, expenses, attorneys' fees and taxes incurred in or arising
out of or related to the subject matter of this Agreement.
17. GOVERNING LAW. This Agreement shall be deemed to have been entered
into, and shall be construed and enforced, in accordance with the laws of the
State of Maryland as applied to contracts made and to be performed entirely in
Maryland
18. FURTHER ACTIONS. The Parties agree to take such other and further
steps as may be necessary or appropriate to assure that the intent of this
Agreement is effectuated.
19. NOTICES. Any statements, communications or notices to be provided
pursuant to this Agreement shall be sent in writing to the attention of the
persons indicated below, until such time as notice of any change of person to be
notified or change of address is forwarded to all Parties;
5.
<PAGE> 6
ONCORMED, INC.
Douglas Dolginow, M.D.
205 Perry Parkway
Gaithersburg, MD 20877
Phone Number: (301) 208-1888
Facsimile: (301) 527-1539
ONCOR, INC.
John Coker
209 Perry Parkway
Gaithersburg, MD 20877
Phone Number; (301)527-2157
Facsimile: (301) 330-3940
20. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, all of which together
shall constitute one and the same instrument.
21. SEVERABILITY. If any provision of this Agreement, or any portion
thereof, is held by a court of competent jurisdiction to be invalid, illegal, or
unenforceable, that provision shall be limited or eliminated to the minimum
extent necessary so that this Agreement and its terms and conditions shall
otherwise remain in full force and effect and enforceable.
[THIS SPACE INTENTIONALLY LEFT BLANK]
6.
<PAGE> 7
IN WITNESS WHEREOF the Parties have duly authorized and caused this
Agreement to be executed on the date set forth below.
ACCEPTED AND AGREED BY: ONCORMED, INC.
/s/ DOUGLAS DOLGINOW, M.D.
-------------------------------------
By: Douglas Dolginow, M.D.
President and Chief Operating
Officer
ONCOR, INC.
/s/ JOHN COKER
-------------------------------------
By: John Coker
Chief Financial Officer
7.
